IRIS Accounts Production v24.3.2.46 08260751 director 28.9.22 26.9.23 26.9.23 true false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh082607512022-09-27082607512023-09-26082607512022-09-282023-09-26082607512021-09-29082607512021-09-302022-09-27082607512022-09-2708260751ns15:EnglandWales2022-09-282023-09-2608260751ns14:PoundSterling2022-09-282023-09-2608260751ns10:Director12022-09-282023-09-2608260751ns10:PrivateLimitedCompanyLtd2022-09-282023-09-2608260751ns10:SmallEntities2022-09-282023-09-2608260751ns10:AuditExempt-NoAccountantsReport2022-09-282023-09-2608260751ns10:SmallCompaniesRegimeForDirectorsReport2022-09-282023-09-2608260751ns10:SmallCompaniesRegimeForAccounts2022-09-282023-09-2608260751ns10:FullAccounts2022-09-282023-09-2608260751ns10:RegisteredOffice2022-09-282023-09-2608260751ns5:CurrentFinancialInstruments2023-09-2608260751ns5:CurrentFinancialInstruments2022-09-2708260751ns5:Non-currentFinancialInstruments2023-09-2608260751ns5:Non-currentFinancialInstruments2022-09-2708260751ns5:ShareCapital2023-09-2608260751ns5:ShareCapital2022-09-2708260751ns5:SharePremium2023-09-2608260751ns5:SharePremium2022-09-2708260751ns5:RetainedEarningsAccumulatedLosses2023-09-2608260751ns5:RetainedEarningsAccumulatedLosses2022-09-2708260751ns5:CostValuation2022-09-2708260751ns5:WithinOneYearns5:CurrentFinancialInstruments2023-09-2608260751ns5:WithinOneYearns5:CurrentFinancialInstruments2022-09-27
REGISTERED NUMBER: 08260751 (England and Wales)






















Alchem Pharma Ltd

Unaudited Financial Statements

for the Period 28 September 2022 to 26 September 2023






Alchem Pharma Ltd (Registered number: 08260751)






Contents of the Financial Statements
for the period 28 September 2022 to 26 September 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 4


Alchem Pharma Ltd

Company Information
for the period 28 September 2022 to 26 September 2023







DIRECTOR: A Lane





REGISTERED OFFICE: Sandy Lane House
Sandy Lane
Boars Hill
Oxford
OX1 5HN





REGISTERED NUMBER: 08260751 (England and Wales)





ACCOUNTANTS: Smailes Goldie
Chartered Accountants
Regent's Court
Princess Street
Hull
East Yorkshire
HU2 8BA

Alchem Pharma Ltd (Registered number: 08260751)

Balance Sheet
26 September 2023

2023 2022
Notes £    £    £    £   
FIXED ASSETS
Investments 4 1 1

CURRENT ASSETS
Debtors 5 339,597 236,485
Cash at bank 1,279 3,665
340,876 240,150
CREDITORS
Amounts falling due within one year 6 165,622 82,782
NET CURRENT ASSETS 175,254 157,368
TOTAL ASSETS LESS CURRENT
LIABILITIES

175,255

157,369

CREDITORS
Amounts falling due after more than one
year

7

30,308

37,387
NET ASSETS 144,947 119,982

CAPITAL AND RESERVES
Called up share capital 50,001 50,001
Share premium 48,667 48,667
Retained earnings 46,279 21,314
SHAREHOLDERS' FUNDS 144,947 119,982

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the period ended 26 September 2023.

The members have not required the company to obtain an audit of its financial statements for the period ended 26 September 2023 in accordance with Section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

Alchem Pharma Ltd (Registered number: 08260751)

Balance Sheet - continued
26 September 2023


The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the director and authorised for issue on 21 January 2025 and were signed by:





A Lane - Director


Alchem Pharma Ltd (Registered number: 08260751)

Notes to the Financial Statements
for the period 28 September 2022 to 26 September 2023

1. STATUTORY INFORMATION

Alchem Pharma Ltd is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Investments are recognised initially at fair value which is normally the transaction price excluding transaction costs. Subsequently, they are measured at fair value through profit or loss if the shares are publicly traded or their fair value can otherwise be measured reliably. Other investments are measured at cost less impairment.

Taxation
Taxation for the period comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Impairment
Assets not measured at fair value are reviewed for any indication that the asset may be impaired at each balance sheet date. If such indication exists, the recoverable amount of the asset, or the asset's cash generating unit, is estimated and compared to the carrying amount. Where the carrying amount exceeds its recoverable amount, an impairment loss is recognised in profit or loss unless the asset is carried at a revalued amount where the impairment loss is a revaluation decrease.

Alchem Pharma Ltd (Registered number: 08260751)

Notes to the Financial Statements - continued
for the period 28 September 2022 to 26 September 2023

3. EMPLOYEES AND DIRECTORS

The average number of employees during the period was 1 (2022 - 1 ) .

4. FIXED ASSET INVESTMENTS
Shares in
group
undertakin
£   
COST
At 28 September 2022
and 26 September 2023 1
NET BOOK VALUE
At 26 September 2023 1
At 27 September 2022 1

5. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade debtors 1,500 2,000
Amounts owed by group undertakings 314,737 208,213
Other debtors 23,360 26,272
339,597 236,485

6. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Bank loans and overdrafts 6,569 5,998
Taxation and social security 558 6,076
Other creditors 158,495 70,708
165,622 82,782

7. CREDITORS: AMOUNTS FALLING DUE AFTER MORE THAN ONE
YEAR
2023 2022
£    £   
Bank loans 30,308 37,387

8. TRANSACTIONS WITH DIRECTORS

Included in other debtors is £nil (2022 - £594) due by the director of the company.